JP2009530306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530306A5 JP2009530306A5 JP2009500525A JP2009500525A JP2009530306A5 JP 2009530306 A5 JP2009530306 A5 JP 2009530306A5 JP 2009500525 A JP2009500525 A JP 2009500525A JP 2009500525 A JP2009500525 A JP 2009500525A JP 2009530306 A5 JP2009530306 A5 JP 2009530306A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- haloalkyl
- alkoxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 67
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 51
- 229910052799 carbon Inorganic materials 0.000 claims description 46
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- 125000001424 substituent group Chemical group 0.000 claims description 34
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 29
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 27
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 25
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- -1 CN Inorganic materials 0.000 claims description 12
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000001769 aryl amino group Chemical group 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- 150000003456 sulfonamides Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 50
- 239000000203 mixture Substances 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 102100021947 Survival motor neuron protein Human genes 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 108020004705 Codon Proteins 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 102000037087 Excitatory amino acid transporters Human genes 0.000 claims 2
- 108091006291 Excitatory amino acid transporters Proteins 0.000 claims 2
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000032536 Pseudomonas Infections Diseases 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000037433 frameshift Effects 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 0 Cc(c(*)c1*)c(*)c(C)c1Br Chemical compound Cc(c(*)c1*)c(*)c(C)c1Br 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78329206P | 2006-03-17 | 2006-03-17 | |
| PCT/US2007/006772 WO2007109211A2 (en) | 2006-03-17 | 2007-03-16 | 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013004082A Division JP2013116901A (ja) | 2006-03-17 | 2013-01-11 | 脊髄性筋萎縮症の治療およびその他用途のための化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009530306A JP2009530306A (ja) | 2009-08-27 |
| JP2009530306A5 true JP2009530306A5 (enExample) | 2010-05-06 |
Family
ID=38477008
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500525A Pending JP2009530306A (ja) | 2006-03-17 | 2007-03-16 | 脊髄性筋萎縮症の治療およびその他用途のための化合物 |
| JP2013004082A Abandoned JP2013116901A (ja) | 2006-03-17 | 2013-01-11 | 脊髄性筋萎縮症の治療およびその他用途のための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013004082A Abandoned JP2013116901A (ja) | 2006-03-17 | 2013-01-11 | 脊髄性筋萎縮症の治療およびその他用途のための化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8110681B2 (enExample) |
| EP (1) | EP2027088A2 (enExample) |
| JP (2) | JP2009530306A (enExample) |
| CN (1) | CN101500995A (enExample) |
| AU (1) | AU2007227398C1 (enExample) |
| BR (1) | BRPI0708801A2 (enExample) |
| CA (1) | CA2645426A1 (enExample) |
| IL (1) | IL194153A0 (enExample) |
| WO (1) | WO2007109211A2 (enExample) |
| ZA (1) | ZA200807936B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009042907A1 (en) * | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| EA018862B1 (ru) * | 2007-10-19 | 2013-11-29 | Янссен Фармацевтика, Н.В. | МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ |
| JP5632612B2 (ja) * | 2007-12-05 | 2014-11-26 | あすか製薬株式会社 | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
| JP5484316B2 (ja) * | 2008-02-28 | 2014-05-07 | 財団法人乙卯研究所 | 芳香族アミド誘導体 |
| US10793515B2 (en) | 2008-03-19 | 2020-10-06 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| US20210130285A1 (en) | 2008-03-19 | 2021-05-06 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| US8986935B2 (en) * | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| GB0909672D0 (en) * | 2009-06-04 | 2009-07-22 | Xention Discovery Ltd | Compounds |
| GB0909671D0 (en) * | 2009-06-04 | 2009-07-22 | Xention Discovery Ltd | Compounds |
| RU2573569C2 (ru) | 2009-12-22 | 2016-01-20 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона |
| WO2012082817A1 (en) * | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| WO2013062028A1 (ja) * | 2011-10-25 | 2013-05-02 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| AU2013203252B2 (en) | 2012-01-27 | 2015-08-20 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| PL2812004T3 (pl) | 2012-02-10 | 2019-01-31 | Ptc Therapeutics, Inc. | Związki do leczenia rdzeniowego zaniku mięśni |
| EP2872493B1 (en) * | 2012-07-13 | 2018-11-14 | Indiana University Research and Technology Corporation | 5,6,7-trimethoxy 4-phenyl quinolin-2-one derivatives for treatment of spinal muscular atrophy |
| US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
| CA2894992A1 (en) * | 2012-12-24 | 2014-07-03 | Ramot At Tel-Aviv University Ltd. | Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same |
| WO2014134419A1 (en) | 2013-03-01 | 2014-09-04 | Gilead Sciences, Inc. | Use of ikach blockers for the treatment of cardiac diseases |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| CN107074817B (zh) | 2014-08-29 | 2023-12-15 | Chdi基金会股份有限公司 | 用于成像亨廷顿蛋白的探针 |
| CN105801556A (zh) * | 2014-12-31 | 2016-07-27 | 上海药谷药业有限公司 | 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法 |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| JP6846363B2 (ja) * | 2015-07-14 | 2021-03-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ２−フェニル−６−イミダゾリル−ピリジン−４−カルボキサミド誘導体及びそのｅａａｔ３阻害剤としての使用 |
| WO2017066103A1 (en) * | 2015-10-16 | 2017-04-20 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| CN113750101A (zh) * | 2015-12-10 | 2021-12-07 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| JP7086942B2 (ja) | 2016-09-12 | 2022-06-20 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
| CA3041038A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| EA201991309A1 (ru) | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| EP3645121B8 (en) | 2017-06-28 | 2025-06-18 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| LT3814357T (lt) | 2018-06-27 | 2024-06-25 | Ptc Therapeutics, Inc. | Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui |
| CN120137971A (zh) | 2019-07-25 | 2025-06-13 | 诺华股份有限公司 | 可调节的表达系统 |
| KR102186761B1 (ko) * | 2020-06-03 | 2020-12-04 | 옙바이오 주식회사 | 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물 |
| EP4251149A4 (en) * | 2020-11-24 | 2024-10-30 | Merck Sharp & Dohme LLC | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS |
| CN115141097A (zh) * | 2022-06-27 | 2022-10-04 | 重庆医药高等专科学校 | 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的生产线系统 |
| CN115304472A (zh) * | 2022-06-27 | 2022-11-08 | 重庆医药高等专科学校 | 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的合成方法 |
| KR102883783B1 (ko) * | 2022-12-15 | 2025-11-12 | 옙바이오 주식회사 | 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물 제조방법 |
| KR102597093B1 (ko) * | 2023-06-07 | 2023-11-03 | 옙바이오 주식회사 | 줄기세포 노화 억제 신규 화합물 및 이의 약학적 용도 |
| CN117740969B (zh) * | 2023-11-30 | 2025-01-10 | 杭州志呈科技有限公司 | 一种吲哚布芬杂质检测方法及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2034240C2 (de) | 1968-03-27 | 1982-12-02 | CIBA-GEIGY AG, 4002 Basel | Isoindolinderivate, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung |
| US3641040A (en) * | 1968-03-27 | 1972-02-08 | Ciba Geigy Corp | Tertiary amino phenyl acetic acids |
| US4126691A (en) | 1968-03-27 | 1978-11-21 | Ciba-Geigy Corporation | Tertiary aminoacids |
| US3542806A (en) | 1968-03-29 | 1970-11-24 | Robins Co Inc A H | 2-(1-substituted-3-pyrrolidinyl)-isoindolines |
| DE2046992A1 (en) * | 1970-09-24 | 1972-03-30 | Merck Patent Gmbh, 6100 Darmstadt | Isoindolinophenyl-alkanoic acid esters and salts - - antiphlogistic, antipyretic and analgesic agents |
| DE2154525A1 (de) * | 1970-11-05 | 1972-06-15 | Carlo Erba S.P.A., Mailand (Italien) | Isoindolinderivate und Verfahren zu ihrer Herstellung |
| FI53702C (fi) * | 1971-11-22 | 1978-07-10 | Erba Carlo Spa | Foerfarande foer framstaellning av isoindolinderivat |
| US3890346A (en) * | 1972-03-22 | 1975-06-17 | Monsanto Co | Process for the preparation of N-arylphthalimidines |
| GB1413173A (en) * | 1972-07-07 | 1975-11-12 | Bp Chem Int Ltd | Polymerisation process |
| US3997669A (en) | 1972-12-26 | 1976-12-14 | Ciba-Geigy Corporation | Tertiary aminoacids |
| JPS5233667A (en) * | 1975-09-11 | 1977-03-14 | Fuji Kagaku Kogyo Kk | Process for preparation of hydrogenated 1-oxo-isoindoline derivatives |
| IT1113035B (it) * | 1979-03-06 | 1986-01-20 | Erba Farmitalia | Esteri c alla 3 - c alla 4 aclhilici di 1-oxo-2- aperta par.graffa p aperta par. quadrata (alfa-metil) -carbossimetil chiusa par. quadrata - fenil chiusa par. graffa- isoindolina |
| JPS5644686A (en) | 1979-09-21 | 1981-04-23 | Hodogaya Chem Co Ltd | Pressure-sensitive reproducing paper |
| JPS5645955A (en) | 1979-09-21 | 1981-04-25 | Hodogaya Chem Co Ltd | 6-(2,3-dihydroisoindol-2-yl)fluoran compound |
| JPS5750960A (en) * | 1980-09-10 | 1982-03-25 | Hisamitsu Pharmaceut Co Inc | Preparation of novel 4- 1-oxo-2-isoindolinyl acetophenone |
| JPS5845088A (ja) | 1981-09-09 | 1983-03-16 | Sumitomo Chem Co Ltd | 記録紙 |
| JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
| JPH03181478A (ja) | 1989-12-08 | 1991-08-07 | Banyu Pharmaceut Co Ltd | ピリドンカルボン酸誘導体 |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5567718A (en) | 1994-08-11 | 1996-10-22 | Hoechst Marion Roussel Inc. | 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors |
| DE69832695T2 (de) * | 1997-03-10 | 2006-09-14 | Loma Linda University Medical Center, Loma Linda | Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit |
| TW533210B (en) | 1998-12-23 | 2003-05-21 | Schering Corp | Substituted oximes and hydrazones as neurokinin antagonists |
| US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| JP2004515494A (ja) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | 治療剤 |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| US20030027867A1 (en) * | 2001-06-29 | 2003-02-06 | Myriad Genetics, Incorporated | Use of R-NSAID compounds for anti-HIV treatment |
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| ATE548354T1 (de) | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
| AU2003301346A1 (en) | 2002-10-17 | 2004-05-04 | The Trustees Of The University Of Pennsylvania | Method of treating neurological diseases and disorders |
| WO2004048332A1 (ja) | 2002-11-26 | 2004-06-10 | Maruishi Pharmaceutical Co., Ltd. | イソインドリン誘導体 |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| WO2006050451A2 (en) | 2004-11-02 | 2006-05-11 | Whitehead Institute For Biomedical Research | Methods and compositions to treat motor neuron disease |
| AU2007211483B2 (en) | 2006-02-03 | 2012-08-16 | Glaxo Group Limited | Benzoisoindole derivatives for the treatment of pain |
| RU2009117701A (ru) | 2006-10-12 | 2010-11-20 | Новартис АГ (CH) | Производные пирролидина в качестве ингибиторов iap |
-
2007
- 2007-03-13 US US12/293,268 patent/US8110681B2/en not_active Expired - Fee Related
- 2007-03-16 WO PCT/US2007/006772 patent/WO2007109211A2/en not_active Ceased
- 2007-03-16 CN CNA2007800155890A patent/CN101500995A/zh active Pending
- 2007-03-16 JP JP2009500525A patent/JP2009530306A/ja active Pending
- 2007-03-16 CA CA002645426A patent/CA2645426A1/en not_active Abandoned
- 2007-03-16 BR BRPI0708801-9A patent/BRPI0708801A2/pt not_active IP Right Cessation
- 2007-03-16 EP EP07753404A patent/EP2027088A2/en not_active Withdrawn
- 2007-03-16 AU AU2007227398A patent/AU2007227398C1/en not_active Ceased
-
2008
- 2008-09-16 IL IL194153A patent/IL194153A0/en unknown
- 2008-09-16 ZA ZA2008/07936A patent/ZA200807936B/en unknown
-
2011
- 2011-12-05 US US13/310,965 patent/US20120083495A1/en not_active Abandoned
-
2013
- 2013-01-11 JP JP2013004082A patent/JP2013116901A/ja not_active Abandoned